Press Release

Morgan Lewis Advises Foresight Biotherapeutics Inc. in Sale to Shire plc

Monday, August 3, 2015

NEW YORK, August 3, 2015: Morgan Lewis represented Foresight Biotherapeutics Inc., a New York-based, privately-held company, in its $300 million sale to Shire plc. Shire acquired the global rights to FST-100, a late-stage, front of the eye therapy, awaiting approval by regulatory agencies, for the treatment of infectious conjunctivitis.

The Morgan Lewis team advising on the transaction was led by partner Steven Navarro. Extended members of the team included partners Phoebe Mounts, Lou Beardell and Harry Robins; of counsel Randall McGeorge; and associates Bryan Keighery, Lydia Lee, Morgan McDevitt, Squire Servance and David Brenneman.